Skip to content
Screener

BioCryst Pharmaceuticals BCRX Return on equity

Discontinued — last reported Q1 '20

Return on equity at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-105.5%+336pp
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-34.3%—
Precigen logo
PrecigenPGEN
-843.6%-1,103pp
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
-325.6%+36.9pp
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-343.8%-1,012pp
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
35.7%+2.6pp

Other financials

Income statement

See full
Revenue$218.3M+33.6%
Gross profit$214.4M+33.5%
Operating income$98.5M+231%
Net income$78.4M+1,442%
EPS (diluted)$0.30+1,400%

Balance sheet

See full
Cash & equivalents$156.4M+73.9%
Total debt$410.9M+59.9%
Total equity-$454.3M-7.8%
Total assets$557.9M+22.0%

Cash flow

See full
Operating cash flow$104.3M+153%
CapEx$209.0K+16.8%
Free cash flow$104.1M+153%

Valuation

See full
Market cap$2.38B+31.6%
Enterprise value$2.63B+33.4%
P/S2.5×-0.7×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-33.3%-43.0pp
Net margin-40.9%-50.2pp
FCF margin39.7%—

Returns & leverage

See full
Debt / equity0.1×—
Current ratio2.3×+0.1×

Where this comes from

Calculated from BioCryst Pharmaceuticals’s reported figures.

net income/total stockholders equity=-882.8%

Based on trailing twelve months.

The source filing: BioCryst Pharmaceuticals’s 10-Q, filed May 11, 2020. Open the filing →

Filed
May 8, 2020, 5:41 PM EDT
Fiscal quarter
Q1 FY2020
Calendar quarter
Q1 2020
Accession
0001171843-20-003557

FAQ

What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.